Establishment and clinical validation of HLA loss early detection technique for measurable residual disease recurrence after haplo-HSCT in acute leukemia patients

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2300071133

Enrollment

Unknown

Registered

2023-05-05

Start date

2023-03-06

Completion date

Unknown

Last updated

2023-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

measurable residual disease recurrence after haplo-HSCT

Interventions

Observation group:None

Eligibility

Sex/Gender

All

Age

14 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) recipient of haplo-HSCT for AL, (2) possessing patient-specific HLA markers, (3) successful engraftment based on the STR chimerism analysis post-transplantation, (4) able to perform routine chimerism test and flow cytometry MRD test during follow-up, (5) the proportion of naive cells below 5% by cell morphology test post-transplantation, and (6) recipient-type recurrence, with the donor chimerism rate = 97%.

Exclusion criteria

Exclusion criteria: (1) no implantation, (2)incomplete transplantion history data,(3) donor-type recurrence, and (4) other cases who did not meet the above inclusion criteria.

Design outcomes

Primary

Measure	Time frame
Genomic loss of patient-specific human leukocyte antigen;	—

Secondary

Measure	Time frame
measurable residual disease;	—

Countries

China

Contacts

Public ContactMing Jiang

First Affiliated Hospital of Xinjiang Medical University

jiangmingyy@126.com+86 13909910116

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026